Andrew M. Goldsweig, MD, MS, FACC, FSCAI, FSVM, RPVI is an associate professor of interventional cardiology and associate cath lab director for structural heart disease at the University of Nebraska Medical Center (UNMC), where he initiated the LAA occlusion and PFO closure programs and performs TAVR and TEER in addition to coronary interventions. His research interests include utilization and outcomes of structural heart disease procedures and multicenter clinical trials. He serves on the international steering committee of the MINT trial and as a site principal investigator for many other clinical trials including TAVR UNLOAD, Optimize PRO, CHAMPION-AF, ASAP TOO, TRANSCEND, PARADIGM, OCCLUFLEX, and the National Cardiogenic Shock Initiative.  Andy serves as Governor of the Nebraska Chapter of the ACC and is a member of the NCDR LAAO Registry Steering Committee and the HeartPAC Executive Board.  He is also a member of the SCAI Structural Heart Disease Council, Publications Committee, and Government Relations Committee, representing SCAI on the AMA CPT Panel.  He is an associate editor for JSCAI and an editorial board member for Circulation: Cardiovascular Interventions, Catheterization and Cardiovascular Interventions, the American Heart Journal and Cardiovascular Revascularization Medicine.